|Mr. Brent Willis||Pres, CEO & Director||62.5k||N/A||1971|
|Mr. Bradley Craig Willis P.Eng.||Founder, COO & VP of Exploration||62.5k||N/A||1971|
|Mr. Ronald Robert Love||Chief Financial Officer||N/A||N/A||N/A|
Voyageur Pharmaceuticals Ltd. focuses on the development of active pharmaceutical ingredients minerals. The company intends to develop barium and iodine radiocontrast products and bromine based pharmaceutical products. It holds 100% interest in three barium sulfate deposits, including two properties suitable in grade for the industrial barite marketplace located in British Columbia, Canada; and interests in a high-grade iodine, lithium, and bromine brine project in Utah, the United States. The company was formerly known as Voyageur Minerals Ltd. and changed its name to Voyageur Pharmaceuticals Ltd. in December 2019. Voyageur Pharmaceuticals Ltd. is based in Calgary, Canada.
Voyageur Pharmaceuticals Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.